CSF N-glycan profiles to investigate biomarkers in brain developmental disorders: application to leukodystrophies related to eIF2B mutations

PLoS One. 2012;7(8):e42688. doi: 10.1371/journal.pone.0042688. Epub 2012 Aug 29.

Abstract

Background: Primary or secondary abnormalities of glycosylation have been reported in various brain diseases. Decreased asialotransferrin to sialotransferrin ratio in cerebrospinal fluid (CSF) is a diagnostic marker of leukodystrophies related to mutations of genes encoding translation initiation factor, EIF2B. We investigated the CSF glycome of eIF2B-mutated patients and age-matched normal individuals in order to further characterize the glycosylation defect for possible use as a biomarker.

Methodology/principal findings: We conducted a differential N-glycan analysis using MALDI-TOF/MS of permethylated N-glycans in CSF and plasma of controls and eIF2B-mutated patients. We found in control CSF that tri-antennary/bisecting and high mannose structures were highly represented in samples obtained between 1 to 5 years of age, whereas fucosylated, sialylated structures were predominant at later age. In CSF, but not in plasma, of eIF2B-mutated patient samples, we found increased relative intensity of bi-antennary structures and decreased tri-antennary/bisecting structures in N-glycan profiles. Four of these structures appeared to be biomarker candidates of glycomic profiles of eIF2B-related disorders.

Conclusion: Our results suggest a dynamic development of normal CSF N-glycan profiles from high mannose type structures to complex sialylated structures that could be correlated with postnatal brain maturation. CSF N-glycome analysis shows relevant quantitative changes associated with eIF2B related disorders. This approach could be applied to other neurological disorders involving developmental gliogenesis/synaptogenesis abnormalities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism*
  • Brain Diseases / cerebrospinal fluid*
  • Brain Diseases / genetics*
  • Calibration
  • Cerebrospinal Fluid / metabolism*
  • Child, Preschool
  • Developmental Disabilities / cerebrospinal fluid*
  • Developmental Disabilities / genetics*
  • Eukaryotic Initiation Factor-2B / genetics*
  • Female
  • Glycosylation
  • Hereditary Central Nervous System Demyelinating Diseases / cerebrospinal fluid*
  • Hereditary Central Nervous System Demyelinating Diseases / genetics*
  • Humans
  • Infant
  • Male
  • Methylation
  • Mutation*
  • Polysaccharides / chemistry*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

Substances

  • Biomarkers
  • Eukaryotic Initiation Factor-2B
  • Polysaccharides

Grants and funding

This work was supported by grants of the European Leukodystrophy Association (ELA) research foundation and the “Leukotreat” European consortium supported by the FP7-Heath program (FP7#241622). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.